2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. ATP Synthase

ATP Synthase

ATP Synthase

Related Products

PDF 0.2 MB

ATPases are a class of enzymes that catalyze the decompositionof ATP into ADP and a free phosphate ion. This dephosphorylation reaction releases energy, which the enzyme (in most cases) harnesses to drive other chemical reactions that would not otherwise occur. Some such enzymes are integral membrane proteins and move solutes across the membrane, typically against their concentration gradient. These are called transmembrane ATPases. Transmembrane ATPases import many of the metabolites necessary for cell metabolism and export toxins, wastes, and solutes that can hinder cellular processes. Such as the sodium-potassium exchanger (or Na+/K+ ATPase) and the hydrogen potassium ATPase (H+/K+ ATPase or gastric proton pump) that acidifies the contents of the stomach.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N6784
    Oligomycin B
    		Inhibitor
    Oligomycin B is an antibiotic that acts as a non-selective inhibitor of ATP Synthase. Oligomycin B increases mitochondrial membrane potential. Oligomycin B induces apoptosis and necrosis. Oligomycin B impairs the motility of Plasmopara viticola zoospores and induces their lysis. Oligomycin B inhibits Magnaporthe oryzae (wheat blast fungus) and suppresses the development of wheat blast. Oligomycin B reduces hyphal growth and spore germination of Botrytis cinerea, and protects Arabidopsis thaliana against Botrytis cinerea infection. Oligomycin B exacerbates cytotoxic brain edema in rats with cerebral cortical contusion, increases intracranial pressure and brain water content, and aggravates mitochondrial damage in these rats. Oligomycin B is used in studies related to grape downy mildew, traumatic brain injury, wheat blast, and gray mold.
    Oligomycin B
  • HY-N125722
    Venturicidin A
    		Inhibitor
    Venturicidin A (Aabomycin A1), from actinomycetes, is a membrane-active natural product inhibitor of ATP synthase. Venturicidin A potentiates the aminoglycoside antibiotic gentamicin against multidrug-resistant clinical isolates of Staphylococcus, Enterococcus, and Pseudomonas aeruginosa. Venturicidin A shows noticeable toxicity toward human embryonic-kidney (HEK)cells with an IC50 of 31 μg/mL.
    Venturicidin A
  • HY-P11005
    P259
    		99.75%
    P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model.
    P259
  • HY-17355B
    Dexpramipexole
    		99.56%
    Dexpramipexole ((R)-Pramipexole) is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.
    Dexpramipexole
  • HY-126679
    Apoptolidin
    		Inhibitor
    Apoptolidin is a polyketide isolated from Nocardiopsis bacteria. Apoptolidin is a selective mitochondrial F1FO ATPase inhibitor. Apoptolidin is an apoptosis inducer and induces apoptotic cell death in cells transformed with the adenovirus type 12 oncogenes including ElA (IC50=10-17 ng/ml) but not in normal cells.
    Apoptolidin
  • HY-158415
    ATPase-IN-4
    		Inhibitor 98.25%
    ATPase-IN-4 (Compound MS1) inhibits the ATPase activity of EHD4 (IC50: 0.92 μM). ATPase-IN-4 also inhibits EHD2 enzymatic activity
    ATPase-IN-4
  • HY-109098
    Parimifasor
    		Inhibitor 98.53%
    Parimifasor (LYC-30937) is an orally active agent for inflammatory bowel disease. Parimifasor targets F1F0-ATPase. Parimifasor acts on respiratory complex V, slows ATP production and induces Apoptosis. Parimifasor can be used in the research of inflammatory bowel disease.
    Parimifasor
  • HY-112715
    ATP synthase inhibitor 1
    		Inhibitor 99.56%
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels.
    ATP synthase inhibitor 1
  • HY-148041
    ATPase-IN-2
    		Inhibitor 98.0%
    ATPase-IN-2 is an ATPase inhibitor with an IC50 value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC50 value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related.
    ATPase-IN-2
  • HY-175839
    PROTAC EGFR degrader 15
    		Agonist 99.23%
    PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984)-based Gefitinib (HY-50895) EGFR PROTAC degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: EGFR ligand (HY-W109039); Blue: CRBN ligand (HY-10984); Black: Linker (HY-W679737)).
    PROTAC EGFR degrader 15
  • HY-P991444
    IPH5201
    		99.24%
    IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors.
    IPH5201
  • HY-136406S
    Bongkrekic acid-13C28
    		Inhibitor 98.0%
    Bongkrekic acid-13C28 is the 13C labeled Bongkrekic acid (HY-136406). Bongkrekic acid is a mitochondrial toxin secreted by the bacteria Pseudomonas cocovenenans. Bongkrekic acid specific ligand for mitochondrial adenine nucleotide translocase (ANT) rather than the electron transport chain. Bongkrekic acid has to cross the mitochondrial inner membrane to produce its inhibitory effect on ADP/ATP transport.
    Bongkrekic acid-<sup>13</sup>C<sub>28</sub>
  • HY-59273
    5-Nitroindole
    		Inhibitor 99.30%
    5-Nitroindole is a mutagenic nitroarene and universal base analog. 5-Nitroindole significantly reduces the cellular adenylate energy charge by decreasing ATP levels and increasing AMP levels. 5-Nitroindole inhibits lipid peroxidation.
    5-Nitroindole
  • HY-10250A
    Triciribine phosphate sodium
    		99.82%
    Triciribine phosphate sodium inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate sodium also inhibits IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity.
    Triciribine phosphate sodium
  • HY-W779800
    D-α-Hydroxyglutaric acid-13C5 (disodium)
    		Inhibitor 98.87%
    D-α-Hydroxyglutaric acid-13C5 disodium is the 13C-labeled D-α-Hydroxyglutaric acid (HY-113038). D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling.
    D-α-Hydroxyglutaric acid-<sup>13</sup>C<sub>5</sub> (disodium)
  • HY-10250
    Triciribine phosphate
    		≥99.0%
    Triciribine phosphate (TCN-P) inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate also inhibits  IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity.
    Triciribine phosphate
  • HY-10250S1
    Triciribine phosphate-d3
    		Inhibitor 99.68%
    Triciribine phosphate-d3 (TCN-P-d3) is a deuterated compound of Triciribine phosphate (TCN-P). TCN-P inhibits adenosine monophosphate (AMP)-activated protein kinase through an allosteric mechanism, affecting the first key step in de novo purine biosynthesis. Triciribine phosphate also inhibits inosine monophosphate dehydrogenase, which is the first key step in guanosine nucleotide synthesis. Triciribine phosphate does not affect ligase activity .
    Triciribine phosphate-d<sub>3</sub>
  • HY-150983
    ATP synthase inhibitor 2
    		Inhibitor 99.93%
    ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL.
    ATP synthase inhibitor 2
  • HY-148973
    ZW290
    		Inhibitor 99.60%
    ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT.
    ZW290
  • HY-146388
    Mtb ATP synthase-IN-1
    		Inhibitor 98.55%
    Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC50 > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium.
    Mtb ATP synthase-IN-1
Cat. No. Product Name / Synonyms Application Reactivity